Acrivon Q3 Loss Narrows to $17.9M; $77.8M Cash Funds Operations Into Q4 2027
ACRV is trading near its 52-week low of $1.27 (14% above the low).
Summary
Acrivon reported a Q3 2026 net loss of $17.9 million and $77.8 million in cash, enough to fund operations into Q4 2027, with the ACR-368 Phase 2b interim analysis still expected in the fourth quarter of 2026.
Key Events · Earnings and Guidance · ACRV
-
Q3 Loss Narrows Slightly
Net loss was $17.9 million for the quarter ended September 30, 2026, versus $18.2 million a year earlier; R&D rose to $14.5 million from $13.6 million while G&A fell to $4.0 million from $6.0 million.
-
Cash Runway Into Q4 2027
Cash, cash equivalents and investments totaled $77.8 million as of September 30, 2026, which management expects to fund operating expenses and capital expenditures into the fourth quarter of 2027.
-
ACR-368 Interim Analysis Due Q4 2026
The prespecified simultaneous interim analysis across the all-comer serous endometrial cancer arms of the Phase 2b study, plus an update of the OncoSignature-positive Arm 1, is expected in the fourth quarter of 2026, with full enrollment of Arm 3 or Arm 4 also targeted then.
-
New CDK11 Candidate ACR-7280 Nominated
Acrivon nominated oral CDK11 inhibitor ACR-7280 for IND-enabling studies, with an IND submission to the FDA planned for the first half of 2027 in AML and peripheral T-cell lymphoma.
Analysis · ACRV · Life Sciences
The cash balance is the headline here: $77.8 million keeps Acrivon funded into the fourth quarter of 2027, past the ACR-368 Phase 2b interim analysis expected in Q4 2026 and the ACR-2316 expansion readouts targeted by mid-2027. Third-quarter loss came in at $17.9 million, slightly better than the $18.2 million loss a year ago, as R&D spending rose to $14.5 million from $13.6 million while G&A fell to $4.0 million from $6.0 million. The quarter also added a new pipeline asset, the oral CDK11 inhibitor ACR-7280, with an IND filing planned for the first half of 2027, and management reiterated that the ACR-525 JAK1 program will seek FDA alignment on a Phase 2 eosinophilic esophagitis trial in the first quarter of 2027. With the stock at $1.45 and a small market capitalization, the runway statement matters more than the modest loss improvement — it removes near-term financing pressure ahead of the ACR-368 data.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACRV was trading at $1.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $62.6M. The 52-week trading range was $1.27 to $3.56. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.